Nonsteroidal anti-inflammatory drugs in colorectal cancer: From prevention to therapy

British Journal of Cancer

Volumn 88, Issue 6, 2003, Pages 803-807

  Ricchi, P ^a   Zarrilli, R ^a   Di Palma, A ^a   Acquaviva, A M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anticancer drugs; Chemoprevention; Colon cancer; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; GEFITINIB; GROWTH FACTOR; INDOMETACIN; IRINOTECAN; LEVAMISOLE; METHOTREXATE; NOLATREXED; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PACLITAXEL; RALTITREXED; ROFECOXIB; SULINDAC; SULINDAC SULFIDE; TOPOTECAN; TRASTUZUMAB;

ABDOMINAL PAIN; APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SELECTIVITY; DYSPEPSIA; HUMAN; HUMAN CELL; LEUKOPENIA; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; GROWTH SUBSTANCES; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SIGNAL TRANSDUCTION;

EID: 0037464333     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600829     Document Type: Short Survey

References (45)

1. Bennett A, Gaffen JD, Melhuish PB, Stamford IF (1987) Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate. Br J Pharmacol 91: 229-235
2. Canman CE, Tang HY, Normolle DP, Lawrence TS, Maybaum J (1992) Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity. Proc Natl Acad Sci 89: 10 474-10 478
3. Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286
4. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
5. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R (2000) IGF-II/IGF receptor pathway upregulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19: 5517-5524
6. Dormond O, Foletti A, Paroz C, Ruegg C (2001) NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7: 1041-1047
7. DuBois RN, Awad J, Morrow J, Roberts II LJ, Bishop PR (1994) Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 93: 493-498
8. Duffy CP, Elliolt CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M (1998) Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34: 1250-1259
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188
10. Elder DJ, Halton DE, Hague A, Paraskeva C (1997) Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3: 1679-1683
11. Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli M, Boracchi P (2001) Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat 65: 71-75
12. Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19: 19-27
13. Gupta RA, DuBois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Review 1: 11-21
14. Han Z, Pantazis P, Wyche JH, Kouttab N, Kidd VJ, Hendrickson EA (2001) Fas-associated death domain protein-dependent mechanism mediates the apoptotic action of non-steroidal anti-inflammatory drugs in the human leukemic Jurkat cell line. J Biol Chem 276: 38 748-38 754
15. He Q, Luo X, Huang Y, Sheikh MS (2002) Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 21: 6032-6040
16. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T (2000) Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6: 2006-2011
17. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11 397-11 403
18. Hung WC, Chang HC, Pan MR, Lee TH, Chuang LY (2000) Induction of p27 (K1P1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol 58: 1398-1403
19. Johnson AJ, song X, Hsu A, Chen C (2001) Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul 41: 221-235.
20. King Jr JG, Khalili K (2001) Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene 20: 6864-6870
21. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959
22. Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249
23. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B (1994) Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602-5606
24. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713-1719
25. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T (2000) Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60: 5303-5309
26. Nicholson DW (2000) From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810-816
27. Nita ME, Tominaga O, Nagawa H, Tsuruo T, Muto T (1998) Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 45: 2117-2122
28. Petak I, Houghton JA (2001) Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 7: 95-106
29. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G (2002) A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50: 857-860.
30. Ricchi P, Pignata S, Di Popolo A, Memoli A, Apicella A, Zarrilli R, Acquaviva AM (1997) Effect of aspirin treatment on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. Int J Cancer 73: 880-884
31. Ricchi P, Di Matola T, Ruggiero G, Zanzi D, Apicella A, di Palma A, Pensabene M, Pignata S, Zarrilli R, Acquaviva AM (2002) Effect of anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs. Br J Cancer 86: 1501-1509
32. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM (2001) The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7: 977-984
33. Sinicrope FA, Pazdur R, Levin B (1996) Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma. Clin Cancer Res 2: 37-41
34. Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M (2000) New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 36: 559-566
35. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94: 585-591
36. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn Jr PA, Chou TC (1999) Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184
37. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.
38. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266
39. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028
40. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27 307-27 314
41. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80
42. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417
43. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J (2002) Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033.
44. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-992
45. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, Fan DM, Lam SK (2001) Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 22: 1393-1397